Introduction
The aortic valve is a valve that separates the main pumping chamber of the heart (the left ventricle) from the large artery that takes oxygen rich blood away from the heart and out to the body (the aorta). If the valve doesn't completely open, it is called aortic stenosis. Aortic stenosis decreases the amount of oxygenated blood getting out to the body. Open surgery is one method of replacing a damaged aortic valve. A newer procedure -known as transcatheter aortic valve replacement or transcatheter aortic valve implantation -has been developed. It allows a replacement valve to be threaded through an artery and into the heart without open heart surgery. A catheter (a long thin, tube) is threaded through an artery, either in the leg or in the chest, and into the heart. The replacement valve is then lodged into the defective aortic valve. The new valve is then expanded, pushing aside parts of the old valve. This policy describes when transcatheter aortic valve replacement may be considered medically necessary.
Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.  Whether transcatheter heart valve system is FDA approved and will be used in a manner consistent with FDA labeling ∞ Severe aortic stenosis: For the use of the Sapien or CoreValve devices, severe aortic stenosis is defined by the presence of one or more of the following criteria:
 An aortic valve area of less than or equal to 1 cm 2  An aortic valve area index of less than or equal to 0.6 cm 2 /m 2  A mean aortic valve gradient greater than or equal to 40 mmHg  A peak aortic-jet velocity greater than or equal to 4.0 m/s
Evidence Review Description
Transcatheter aortic valve implantation (TAVI; also known as transcatheter aortic valve replacement) is a potential treatment for patients with severe aortic stenosis. Many patients with aortic stenosis are elderly and/or have multiple medical comorbidities, thus indicating a high, often prohibitive, risk for surgery. This procedure is being evaluated as an alternative to open surgery, or surgical aortic valve replacement (SAVR), for high-risk patients with aortic stenosis and as an alternative to nonsurgical therapy for patients with a prohibitive risk for surgery.
Background

Aortic Stenosis
Aortic stenosis is defined as narrowing of the aortic valve opening, resulting in obstruction of blood flow from the left ventricle into the ascending aorta. Progressive calcification of the aortic valve is the most common etiology in North America and Europe, while rheumatic fever is the most common etiology in developing countries. 1 
Disease Burden
Aortic stenosis is a relatively common disorder in elderly patients and is the most common acquired valve disorder in the United States. Approximately 2% to 4% of people older than 65 years of age have evidence of significant aortic stenosis, 1 increasing up to 8% of people by age 85 years. 2 In the Helsinki Aging Study (1993), a population-based study of 501 patients ages 75
to 86 years, the prevalence of severe aortic stenosis by echocardiography was estimated to be 2.9%. 3 In the United States, more than 50,000 aortic valve replacements are performed annually due to severe aortic stenosis.
Aortic stenosis does not cause substantial morbidity or mortality when the disease is mild or moderate in severity. By the time it becomes severe, there is an untreated mortality rate of approximately 50% within 2 years. 4 Open surgical repair is an effective treatment for reversing aortic stenosis, and artificial valves have demonstrated good durability for periods of up to 20 years. 4 However, these benefits are accompanied by a perioperative mortality of approximately 3% to 4% and substantial morbidity, 4 both of which increase with advancing age.
Unmet Needs
Many patients with severe, symptomatic aortic stenosis are poor operative candidates.
Approximately 30% of patients presenting with severe aortic stenosis do not undergo open surgery due to factors such as advanced age, advanced left ventricular dysfunction, or multiple medical comorbidities. 5 For patients who are not surgical candidates, medical therapy can partially alleviate the symptoms of aortic stenosis but does not affect the underlying disease progression. Percutaneous balloon valvuloplasty can be performed, but this procedure has less than optimal outcomes. 6 Balloon valvuloplasty can improve symptoms and increase flow across the stenotic valve but is associated with high rates of complications such as stroke, myocardial infarction, and aortic regurgitation. Also, restenosis can occur rapidly, and there is no improvement in mortality. As a result, there is a large unmet need for less invasive treatments for aortic stenosis in patients who are at increased risk for open surgery.
∞ Treatment
Transcatheter aortic valve implantation has been developed in response to this unmet need and was originally intended as an alternative for patients for whom surgery was not an option due to prohibitive surgical risk or for patients at high risk for open surgery. The procedure is performed percutaneously, most often through the transfemoral artery approach. It can also be done through the subclavian artery approach and transapically using mediastinoscopy. Balloon valvuloplasty is first performed to open up the stenotic area. This is followed by passage of a bioprosthetic artificial valve across the native aortic valve. The valve is initially compressed to allow passage across the native valve and is then expanded and secured to the underlying aortic valve annulus. The procedure is performed on the beating heart without cardiopulmonary bypass. For individuals with valve dysfunction and aortic stenosis or regurgitation after aortic valve repair who receive transcatheter aortic "valve-in-valve" implantation, the evidence includes case series (largest with 459 patients) and systematic reviews of case series. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related mortality and morbidity. These case series have reported high rates of technical success of valve implantation and improvement in heart failure symptoms for most patients. However, they have also reported high rates of short-term complications and high rates of mortality at 1 year postprocedure. There is a lack of evidence comparing valve-in-valve replacement with alternative treatment approaches. The evidence is insufficient to determine the effects of the technology on health outcomes.
Summary of Evidence
Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this policy are listed in Table 1 . 
Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.
Input
In response to requests, clinical input was received from 2 specialty societies (1 of which provided 2 responses) and 2 academic medical centers (1 of which provided 3 responses) while this policy was under review in 2016. Although there was no support for the use of valve-invalve transcatheter aortic valve implantation (TAVI) to replace a failed bioprosthetic valve in general use, there was general support for the use of valve-in-valve TAVI for patients at high and prohibitive risk for surgery.
In response to requests, clinical input was received from 2 specialty societies ( had not yet been granted for any TAVI device. Reviewers were mixed in support for a medically necessary indication for patients who are not surgical candidates. However, all reviewers indicated that they would consider this procedure medically necessary if FDA granted approval.
No reviewer expressed support for medical necessity in other patient populations, including patients who were at high risk for surgery, but were surgical candidates. Concerning patient selection criteria, most reviewers referred to the study selection criteria in the PARTNER trial and did not offer further options for objective patient selection.
Practice Guidelines and Position Statements
American College of Cardiology and the American Heart Association
The American College of Cardiology and the American Heart Association (2014) published joint guidelines on the management of valvular heart disease. 85 Both groups issued a joint focused update in 2017. 86 These guidelines make the following recommendations on the choice of surgical or transcatheter intervention for treatment of aortic stenosis (see Table 2 ).  Two cardiac surgeons agree with indications for the procedure.
 The patient is "under the care of a heart team," and the hospital meets qualifications for performing TAVR.
The memo also stated that TAVR could be covered for non-FDA-approved indications under the Coverage with Evidence Development program. The following is a summary of the main conditions required for Coverage with Evidence Development:
 TAVI is performed within a clinical study that has the following characteristics:
o "The clinical study must adhere to the… standards of scientific integrity and relevance to the Medicare population."
o The study must address quality of life and adverse events at follow-up periods of 1 year or longer.
∞
Regulatory Status
Two manufacturers have transcatheter aortic valve devices with Food and Drug Administration (FDA) approval. Regulatory status data for these devices are listed in Table 3 . Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply.
CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2019 Premera All Rights Reserved.
Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law
LifeWise Health Plan of Washington complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.
LifeWise:
• Provides free aids and services to people with disabilities to communicate effectively with us, such as:
• Qualified sign language interpreters • Written information in other formats (large print, audio, accessible electronic formats, other formats) • Provides free language services to people whose primary language is not English, such as:
• Qualified interpreters • Information written in other languages
If you need these services, contact the Civil Rights Coordinator.
If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator -Complaints and Appeals PO Box 91102, Seattle, WA 98111 Toll free 855-332-6396, Fax 425-918-5592, TTY 800-842-5357 Email AppealsDepartmentInquiries@LifeWiseHealth.com
